Integrative and comparative single-cell analysis reveals transcriptomic difference between human tumefactive...

Area of Science:

• Neuroimmunology
• Oncology
• Transcriptomics

Background:

• Tumefactive demyelinating lesions (TDL) are immune-mediated conditions often misdiagnosed as glioma.
• A cellular-level comparison between TDL and glioma is currently lacking.
• Understanding these differences is crucial for accurate diagnosis and treatment.

Purpose of the Study:

• To conduct an integrative and comparative single-cell RNA sequencing (ScRNA-seq) analysis of TDL and glioma lesions.
• To identify distinct cellular compositions and functions in TDL versus glioma.
• To elucidate the role of specific cell subsets in TDL pathogenesis.

Main Methods:

• Single-cell RNA sequencing (ScRNA-seq) transcriptomic analysis.
• Integrative and comparative analysis of TDL and glioma samples.
• Subclustering and pseudotime trajectory analysis for T cells.

Main Results:

• TDL lesions are predominantly composed of immune cells, contrasting sharply with glioma.
• A TDL-specific microglial subset was identified, implicated in B cell activation.
• Glial cells showed remyelination functions, while T cells exhibited demyelination functions in TDL.
• T cells in TDL displayed significant heterogeneity and diverse roles in disease progression and recovery.

Conclusions:

• Substantial cellular-level differences exist between TDL and glioma.
• TDL involves a complex interplay of immune cells with specific functions in remyelination and demyelination.
• Cellular heterogeneity in TDL is critical for understanding disease progression and potential therapeutic strategies.